Renovacor

Renovacor, Inc. operates as a clinical stage gene therapy company. It researches and develops AAV-based gene therapies for BAG3 gene mutation-associated diseases. Its therapeutic focus is on cardiovascular diseases. The company was founded by Arthur Michael Feldman on June 7, 2013 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rocket Pharma

CRANBURY, N.J.--( BUSINESS WIRE )--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that it has completed the previously announced acquisition of Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Under the terms of the merger agreement entered into on September 19, 2022, Renovacor shareholders received, for each share of Renovacor common stock, 0.1763 shares of Rocket common stock.

Rocket Pharmaceuticals Completes Acquisition of Renovacor

NEW ORLEANS , Nov. 3, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

RENOVACOR INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Renovacor, Inc. - RCOR

Channeladvisor

Archaea Energy

CarLotz

NEW YORK , Nov. 3, 2022 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Weiss Law305 Broadway, 7th Floor New York, NY 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Archaea Energy Inc. (NYSE: LFG) Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Archaea Energy Inc. (NYSE: LFG) in connection with the proposed acquisition of LFG by BP p.l.c.

SHAREHOLDER ALERT: Weiss Law Reminds LFG, ECOM, LOTZ, and RCOR Shareholders About Its Ongoing Investigations

Southern Missouri Bancorp

Talos Energy Inc

NEW YORK , Nov. 2, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Renovacor, Inc. (NYSE: RCOR)'s  sale to Rocket Pharmaceuticals, Inc. for approximately 0.1676 shares of Rocket for each Renovacor share. Upon completion of the transaction, Renovacor shareholders are expected to own approximately 4.6% percent of Rocket.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RCOR, SMBC, TALO

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that the results of analytical and biophysical assays conducted as part of the company's chemistry, manufacturing, and controls (CMC) development process for REN-001 will be featured in an upcoming poster presentat

Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress

First Eagle Alternative Capital BDC Inc

STORE Capital

NEW YORK , Oct. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: STORE Capital Corporation (NYSE: STOR)'s  sale to GIC and funds managed by Oak Street for $32.25 per share in cash. If you are a STORE Capital shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STOR, RCKT, RCOR, FCRD

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that preclinical studies characterizing the progression of cardiac dysfunction and mortality in a BAG3 haploinsufficiency mouse model of dilated cardiomyopathy will be featured in an upcoming poster presentation at

Renovacor Announces Upcoming Presentation at Keystone Symposia's Heart Failure: Mechanisms and Therapies Conference

NEW YORK , Sept. 22, 2022 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Renovacor, Inc. (RCKT), relating to its proposed acquisition by Rocket Pharmaceuticals, Inc. Under the terms of the agreement, RCKT shareholders will receive 0.1676 shares of Rocket per share they own.

The M&A Class Action Firm Announces an Investigation of Renovacor, Inc. - RCKT

Wilmington, Delaware--(Newsfile Corp. - September 21, 2022) - Rigrodsky Law, P.A. is investigating Renovacor, Inc. ("Renovacor") (NYSE: RCOR) regarding possible breaches of fiduciary duties and other violations of law related to Renovacor's agreement to be acquired by Rocket Pharmaceuticals, Inc.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-renovacor-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Renovacor, Inc. Buyout

MILWAUKEE , Sept. 21, 2022 /PRNewswire/ -- Ademi LLP is investigating Renovacor (NYSE: RCOR) for possible breaches of fiduciary duty and other violations of law in its transaction with Rocket Pharmaceuticals.

Shareholder Alert: Ademi LLP investigates whether Renovacor, Inc. has obtained a Fair Price in its transaction with Rocket Pharmaceuticals, Inc.

NEW YORK , Sept. 20, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Renovacor, Inc. ("Renovacor" or the "Company") (NYSE: RCOR), in connection with the proposed acquisition of the Company by Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals") (NASDAQ: RCKT).

SHAREHOLDER ALERT: Weiss Law Investigates Renovacor, Inc.

Source: Shutterstock.com Renovacor (NYSEMKT: RCOR ) stock is gaining on Tuesday after announcing that Rocket Pharmaceuticals (NASDAQ: RCKT ) is acquiring it. That agreement will have Rocket Pharmaceuticals offering 0.1676 shares of RCKT stock in exchange for each outstanding share of RCOR stock.

Why Is Renovacor (RCOR) Stock Up 18% Today?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Renovacor, Inc. (NYSE: RCOR) to Rocket Pharmaceuticals, Inc. for approximately 0.1676 shares of Rocket for each Renovacor share is fair to Renovacor shareholders. Upon completion of the transaction, Renovacor shareholders are expected to own approximately 4.6% percent of Rocket. Halper Sadeh encourages Renovacor shareholders to click here to learn more about their legal rights and opti

RCOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Renovacor, Inc. Is Fair to Shareholders

CRANBURY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, and Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related

Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today reported financial results for the second quarter of 2022 and provided a corporate update. “The progress achieved at Renovacor this quarter enabled us to advance and expand our pipeline of precision AAV gene therapies that t

Renovacor Reports Second Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced it has expanded its pipeline to advance an AAV gene therapy program as a potential precision therapy for three genetic segments of arrhythmogenic cardiomyopathy (ACM). To accelerate this new program, Renovacor has

Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic Cardiomyopathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced the publication of the results of a preclinical study demonstrating cardiac transduction with low-doses of REN-001 delivered via retrograde coronary sinus infusion (RCSI) in healthy Yucatan pigs. The paper, titled,

Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of Cardiology: Basic to Translational Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today reported financial results for the first quarter of 2022 and provided a corporate update. “Our first quarter progress was highlighted by REN-001's continued advancement towards the clinic and by the addition of industry vete

Renovacor Reports First Quarter 2022 Financial Results and Provides Corporate Update

PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced the appointment of Fred Driscoll as Chief Financial Officer (CFO). “Fred has a wealth of experience guiding financial strategy for publicly-traded biotech companies and we are thrilled to welcome him to Renovacor,” sai

Renovacor Announces the Appointment of Fred Driscoll as Chief Financial Officer

PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today reported financial results for the fourth quarter and full year 2021. “Throughout 2021, we continued to build on a strong foundation for sustained growth by achieving key scientific and corporate milestones,” said Magdalene Cook

Renovacor Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that Magdalene Cook, M.D., Chief Executive Officer, will present a corporate overview at the 42nd Annual Cowen Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET. A webcast of the presentation will be ava

Renovacor to Present at the 42nd Annual Cowen Health Care Conference

PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced partnerships with the Dilated Cardiomyopathy (DCM) Foundation, the Heart Failure Society of America (HFSA) and the American Association of Heart Failure Nurses (AAHFN). The company will provide sponsorship for initiati

Renovacor Announces Partnerships with the Dilated Cardiomyopathy Foundation, the Heart Failure Society of America and the American Association of Heart Failure Nurses to Help Increase Awareness of Genetic Heart Disorders

PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases, today announced that Magdalene Cook, M.D., President and Chief Executive Officer of Renovacor, will participate in a panel presentation at the 11th Annual LifeSci Partners Corporate Access Event. Details on the panel are shown below: Title: Gene Ther

Renovacor to Participate in a Panel Presentation at the 11th Annual LifeSci Partners Corporate Access Event

PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases, today announced financial results for the third quarter of 2021 and provided a corporate update. “We believe the transformative milestones we've achieved over the past several months position us well for near-term and sustained success,” said Magdale

News for Renovacor Stock (RCOR)